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Abstract: Alzheimer’s disease (AD) has shown altered immune responses in the periphery. We
studied P2X7 (a proinflammatory receptor and a scavenger receptor) and two integrins, CD11b and
CD11c, on the surface of circulating leukocytes and analysed their associations with Aβ-PET, brain
atrophy, neuropsychological assessments, and cerebrospinal fluid (CSF) biomarkers. Total 287 agematched, sex-balanced participants were recruited in a discovery cohort and two validation cohorts
through the AIBL study and studied using tri-colour flow cytometry. Our results demonstrated
reduced expressions of P2X7, CD11b, and CD11c on leukocytes, particularly monocytes, in Aβ +ve
cases compared with Aβ −ve controls. P2X7 and integrin downregulation was observed at preclinical stage of AD and stayed low throughout disease course. We further constructed a polygenic
risk score (PRS) model based on 12 P2RX7 risk alleles to assess the genetic impact on P2X7 function
in AIBL and ADNI cohorts. No significant association was identified between the P2RX7 gene and
AD, indicating that P2X7 downregulation in AD is likely caused by environmental changes rather
than genetic factors. In conclusion, the downregulation of P2X7 and integrins at pre-clinical stage of
AD indicates altered pro-inflammatory responses, phagocytic functions, and migrating capabilities of
circulating monocytes in early AD pathogenesis. Our study not only improves our understanding
of peripheral immune involvement in early stage of AD but also provides more insights into novel
biomarker development, diagnosis, and prognosis of AD.
Keywords: myeloid cells; purinergic receptors; episodic memory; the Preclinical Alzheimer’s
Cognitive Composite (PACC); CSF T-tau; CSF Aβ1-42 ; CSF P-tau181P; brain atrophy

This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

1. Introduction
Alzheimer’s disease (AD) is the leading form of dementia, characterised by impairment in learning, memory, and performance of daily activities [1]. The cardinal pathological
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hallmarks of AD include neurofibrillary tangles and beta-amyloid (Aβ) plaques in the
brain [1]. The imbalanced production and clearance of neurotoxic Aβ peptides is a very
early, initiating factor in AD [2,3]. Pathological Aβ accumulation, especially Aβ1-40 and
Aβ1-42 , stimulates microglial and astrocytic activation and pro-inflammatory responses to
clear Aβ [2,3]. These gradually altered immune cells and inflammatory responses drive disease progression before AD symptoms are observed, as supported by genetic studies [1,3,4].
These early biological changes can occur up to 30 years before the appearance of AD clinical
symptoms [5,6], making this preclinical stage of the disease ideal for both understanding
and potentially treating AD. Our research goal is to understand immune involvement in
preclinical and prodromal AD, improve the clinical pathological model of AD, and further
provide potential insights into biomarker discovery and therapeutic development.
Recent genome-wide association studies (GWAS) of AD have discovered over 130 genomic loci associated with AD, demonstrating their roles in microglial phagocytosis of
Aβ, particularly phagocytic receptors and endolysosomal network of the innate immune
system [4,7]. In addition to the interaction between Aβ, tau, and glial cells in AD brain,
new evidence demonstrates the crosstalk between the central nervous system (CNS) and
the peripheral blood and immune system in AD. As AD progresses, increased vascular
permeability of blood-brain barriers (BBB) allows for a selective entry of peripheral immune
cells into the CNS [8]. Peripheral monocytes and T lymphocytes are suggested to infiltrate
into the CNS, modulate inflammatory responses, and promote microglial phagocytosis
of Aβ in mice models of AD [9]. Cerebral Aβ can be transported into the peripheral pool
via BBB, cerebrospinal fluid (CSF), arachnoid villi, and glymphatic-lymphatic system [10].
Nearly half of cerebral Aβ can be exported into the peripheral circulation to be cleared by
enzymes, immune cells, tissues, or organs [4]. The genomic studies of AD have demonstrated monocyte-specific enrichment of AD risk variants, indicating that AD risk variants
may locate in the regulatory regions to modulate monocytic function [4]. Our group also
reported the first human evidence that the basal phagocytic ability of monocytes was associated positively with cerebral Aβ burden in AD patients [11]. Hyperactivation of monocytes
were observed in the prodromal stage of AD, including increased chemotaxis, free radical
production, and cytokine production [12]. These findings all suggest that the phagocytic
function and pro-inflammatory responses of peripheral monocytes are associated with Aβ
burden during AD progression.
This study aimed at understanding the peripheral immune involvement in AD, regarding the phagocytic function and pro-inflammatory responses of innate immune cells.
Our group has studied P2X purinoceptor 7 (P2X7) for decades, which is a dual-functional
purinergic receptor that acts as an ATP-induced pro-inflammatory ion channel and a scavenger receptor responsible for phagocytosing apoptotic cells and debris [13]. Additionally,
recent AD GWAS has nominated many microglial-specific risk genes, including CD11b
(integrin alpha M, ITGAM, or αM ) and CD11c (integrin alpha X, ITGAX, or αX ), which
are integrins responsible for phagocytosis mediated by complement system and the recruitment and migration of monocytes [4]. Given that AD GWAS and functional studies
all indicate the role of phagocytosis in AD, the performance of P2X7, CD11b, and CD11c
on professional phagocytes was the primary aim of this study, including monocytes and
neutrophils. The role of adaptive immune system in AD has also been documented [4], so
T lymphocytes, B lymphocytes, and natural killer (NK) cells were also cell types of interest. Given that Aβ plays a predominant role in the preclinical, prodromal, and dementia
stages of the disease [14] and positron emission tomography (PET)-Aβ imaging (measured
by Centiloid [CL]) provides the most accurate diagnosis of AD [15], the performance of
P2X7, CD11b, and CD11c were compared by PET-Aβ status (−ve: ≤25 CL/+ve: >25 CL),
followed by further comparisons by symptoms(cognitively normal [CN] −ve, CN +ve,
mild cognitive impairment [MCI] −ve, and dementia [MCI +ve and AD]). In addition to
PET-Aβ imaging, brain atrophy assessed by magnetic resonance imaging (MRI), cognitive
decline assessed by neuropsychological scores (episodic memory [EM] and the Preclinical
Alzheimer’s Cognitive Composite [PACC]), and CSF measurements of Aβ1-42 , total tau
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(T-tau), and tau phosphorylated at threonine 181 (P-tau181P) all reflect the natural history of
AD in the three major stages [6]. Therefore, we further evaluated the associations between
our receptors of interests, MRI volumetrics, EM, PACC, and CSF biomarkers to study their
roles in disease course.
2. Results
2.1. P2X7 Downregulation in AD
2.1.1. Reduced Leukocyte Surface P2X7 Expression in Aβ +Ve Cases in Discovery Cohort
We drew at random 88 participants from the Australian Imaging, Biomarker & Lifestyle
Flagship Study of Ageing (AIBL) study (Table 1) and we used APC-conjugated anti-P2X7 antibodies to study the surface expression of P2X7 on peripheral leukocytes. The main results
of these comparisons were shown in Figure 1. Monocyte surface expression of P2X7 was
reduced significantly in Aβ +ve cases compared with Aβ −ve controls (Figure 1A). Regarding subpopulations of monocytes, P2X7 expressions on CD14+ CD16− classical monocytes,
CD14dim CD16+ non-classical monocytes, and CD14+ CD16+ intermediate monocytes were
all reduced in Aβ +ve cases compared with Aβ −ve controls with effect sizes of −0.487,
−0.503, and −0.514, respectively (Figure 1A; Table S1). Also, P2X7 surface expression on
non-classical monocytes was the lowest while that on intermediate monocytes was the
highest among monocyte subtypes (Figure 1A). This cohort was further categorised into CN
−ve, CN +ve, and dementia (MCI +ve and AD) groups. P2X7 expressions on monocyte subpopulations were significantly different between the three groups (Figure 1B–D), in which
P2X7 expression on classic monocytes in CN +ve group and dementia group had effect sizes
of −0.564 and −0.672, respectively (Table S2). While the distribution of P2X7 expression
was spreading in three groups, more CN −ve individuals presented high P2X7 level, while
more CN +ve and dementia individuals presented low P2X7 level (Figure 1B–D). Moreover,
P2X7 expression on classical monocytes trended towards a positive association with PACC,
while P2X7 expressions on other monocyte subpopulations failed to be associated with
PACC (Figure 1E–G). Regarding CSF biomarkers, P2X7 expression on non-classical monocytes was associated negatively with Aβ1-42 /T-tau ratio in CSF, while P2X7 expressions
on other monocyte subpopulations trended towards negative associations with this CSF
biomarker (Figure 1H–J).
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Table 1. Demographic characteristics of our participants.
Discovery

Demographics
Sample size, n (%)
Age in years, mean (SD)
Sex (female), n (%)
APOE ε4, n (%)
Years of education, mean (SD)
Aβ burden, CL mean (SD)
CN, n (%)
MCI, n (%)
AD, n (%)
EM, mean (SD)
Slope of EM, mean (SD)
PACC, mean (SD)
Slope of PACC, mean (SD)
1

Control (≤25 CL)

Case (>25 CL)

29 (39.7)
73.9 (4.3)
11 (37.9)
7 (24.1)
12.4 (2.9)
1.7 (13.5)
28 (96.6)
0 (0.0)
1 (3.4)
0.0 (0.7)
0.0 (0.1)
0.0 (0.7)
0.0 (0.1)

44 (60.3)
76.9 (7.4)
22 (50.0)
20 (45.5)
12.3 (2.8)
78.8 (33.1)
22 (50.0)
15 (34.1)
7 (15.9)
−0.9 (1.3)
−0.1 (0.2)
−0.8 (1.2)
−0.2 (0.2)

p1
0.0343
ns
0.0975
ns
<0.0001
0.0006
0.0005
0.0006
0.0004

Validation A 2
Control (≤25 CL)

Case (>25 CL)

69 (64.5)
73.7 (6.6)
39 (56.5)
13 (18.8)
14.7 (3.4)
2.2 (7.8)
60 (87.0)
5 (7.2)
4 (5.8)
0.1 (0.9)
0.1 (0.2)
0.0 (0.9)
0.1 (0.2)

38 (35.5)
77.4 (8.8)
19 (50.0)
18 (47.3)
13 (3.1)
102.1 (41.2)
16 (42.1)
9 (26.7)
13 (34.2)
−1.3 (1.6)
0.0 (0.2)
−1.6 (1.6)
−0.1 (0.2)

p
0.0253
ns
0.0025
0.0174
<0.0001
<0.0001
0.0176
<0.0001
0.0003

Validation B 3
Control (≤25 CL)

Case (>25 CL)

42 (47.7)
73.6 (13.2)
18 (42.9)
6 (14.3)
13.7 (3.4)
3.7 (8.3)
36 (85.7)
5 (11.9)
1 (2.4)
−0.5 (1.0)
0.0 (0.1)
−0.1 (0.8)
0.0 (0.1)

46 (52.3)
73.5 (13.1)
17 (37.0)
29 (63.0)
12.5 (3.1)
96.4 (44.5)
8 (17.4)
16 (34.8)
22 (47.8)
−0.9 (1.6)
−0.1 (0.3)
−1.0 (1.4)
−0.1 (0.3)

p
ns
ns
0.0005
ns
<0.0001
ns
ns
ns
ns

Based on t-test for continuous variables and chi-square test for categorical variables. Same for all columns named with “p”. 2 For validating P2X7 results. 3 For validating HLA-DR
results. ns: no significance.
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Figure 1. P2X7 expressions on monocytes in the discovery cohort. (A) P2X7 expressions on total
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Figure 1.
P2X7 expressions
on −monocytes
in the
discovery
cohort.
(A) P2X7
expressions on total
+ non-classical
monocytes
(left 1), CD14+CD16
classical monocytes
(left
2), CD14dimCD16
monocytes
+
−
dim
+
monocytes (left 1), CD14 CD16 classical monocytes (left 2), CD14 CD16 non-classical monocytes
(right 2), and CD14+ CD16+ intermediate monocytes (right 1) between Aβ −ve controls (Aβ−) and
Aβ +ve cases (Aβ+). Bar graphs illustrated the boxplot distribution of individual measurements with
“x” denoting the mean. Two group comparison was determined by t-test. (B–D) P2X7 expressions on
classical monocytes, non-classical monocytes, and intermediate monocytes between CN (CN−: CN
−ve), pre-clinical (CN+: CN +ve), and AD with dementia (Dementia: MCI +ve and AD) individuals.
Bar graphs illustrated the boxplot distribution of individual measurements with “x” denoting the
mean. Three-group comparison was determined by one-way ANOVA followed by multiple comparison using Dunnett’s post-hoc test (solid line). (E–J) Associations between monocyte P2X7 expressions,
PACC, and CSF biomarker. Correlation r and p values were calculated by Pearson product-moment
correlational analysis. The “grey” band indicated the 95% confidence interval of the black linear
regression line. ns: no significance.

product-moment correlational analysis. The “grey” band indicated the 95% confidence interval of
the black linear regression line. ns: no significance.

Of note, in CN −ve group, a bimodal distribution of P2X7 expression was observed,
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which was separated by the mean of mean fluorescence intensity (MFI) of P2X7 on classical monocytes (Figure 1B). The group below the mean demonstrated similar P2X7 expresOf note, in CN −ve group, a bimodal distribution of P2X7 expression was observed,
sions compared to CN
+ve and dementia individuals. Therefore, we arbitrarily separated
which was separated by the mean of mean fluorescence intensity (MFI) of P2X7 on classical
CN −ve group into
two populations,
the
over the mean
as P2X7-high
monocytes
(Figure 1B). Thedefining
group below
thecohort
mean demonstrated
similar P2X7
expressions CN
compared
to the
CN +ve
and dementia
individuals.
Therefore,
we arbitrarily
CN Aβ
−ve and the cohort
below
mean
as P2X7-low
CN −ve
(Figure
1B). Weseparated
compared
−ve group into two populations, defining the cohort over the mean as P2X7-high CN
burden, brain volumetrics, and neuropsychological assessments to characterise the P2X7−ve and the cohort below the mean as P2X7-low CN −ve (Figure 1B). We compared
1-42/Tlow CN −ve group.
P2X7-low
−ve individuals
presented assessments
significantly
higher Aβ
Aβ burden,
brainCN
volumetrics,
and neuropsychological
to characterise
the
P2X7-low CN
−vein
group.
CN −
ve individuals
presented
significantly
higher(Figtau and Aβ1-42/P-tau181P
ratios
CSFP2X7-low
compared
with
P2X7-high
CN +ve
individuals
Aβ1-42 /T-tau and Aβ1-42 /P-tau181P ratios in CSF compared with P2X7-high CN +ve
ure 2A,B). Moreover, these individuals were likely to present higher Aβ burden and lower
individuals (Figure 2A,B). Moreover, these individuals were likely to present higher Aβ
T-tau burden in CSF
(Figure
2C,D).
burden
and lower
T-tau burden in CSF (Figure 2C,D).
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Figure 2. Characteristics
P2X7-low of
CN
−ve and
CN −ve
groups
ininthe
discovery
cohort.
(A)
CSF
Aβ
/T-tau
ratio.
(B)
CSF
Aβ
/P-tau181P
ratio.
(C)
CSF
Aβ
concentration
(µg/L).
1-42 CSF Aβ1-42/P-tau181P
1-42 ratio. (C) CSF Aβ1-42 concentration
1-42
(A) CSF Aβ1-42/T-tau ratio. (B)
(μg/L). (D)
(D) CSF T-tau concentration (µg/L). Two group comparison was determined by t-test.
CSF T-tau concentration (μg/L). Two group comparison was determined by t-test.

Second, P2X7 expressions on total neutrophils and CD16++ neutrophils were also
reduced
significantly
Aβ +ve
cases compared
withCD16
Aβ −++
ve neutrophils
controls with effect
sizes
of reSecond, P2X7
expressions
onintotal
neutrophils
and
were
also
−0.581 and −0.625, respectively (Figure 3A; Table S1). Most importantly, P2X7 on CD16++
duced significantly
in Aβ +ve cases compared with Aβ −ve controls with effect sizes of
neutrophils were significantly lower in CN +ve group and dementia group compared with
−0.581 and −0.625,
3A;
Table
S1).−1.067,
Mostrespectively
importantly,
P2X7
on S2).
CD16++
CNrespectively
−ve group, with(Figure
effect sizes
of −
1.171 and
(Figure
3B; Table
Lymphocyte surface expression of P2X7 also demonstrated similar results. P2X7
expression on CD14− total lymphocytes, CD14− CD16+ NK cells, and CD14− CD16− T and
B lymphocytes were reduced significantly in Aβ +ve cases compared with Aβ −ve controls
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with effect sizes of −0.572, −0.509, and −0.559, respectively (Figure 4A; Table S1). P2X7
7 of
23
on NK cells were the highest among lymphocyte subtypes (Figure 4A),
which
was significantly lower in CN +ve and dementia groups compared with CN −ve group,
with effect sizes of −0.550 and −0.758, respectively (Figure 4B; Table S2). Moreover, P2X7
expressions
all lymphocyte
were
associated
positively
neuropsychological
neutrophilson
were
significantlysubtypes
lower in CN
+ve
group and
dementiawith
group
compared with
score
(PACC)
(Figure
4C–E).
CN −ve
group,
with effect
sizes of −1.171 and −1.067, respectively (Figure 3B; Table S2).

Int. J. Mol. Sci. 2022, 23, x FOR PEER
REVIEW
expression

Figure3.3.P2X7
P2X7expressions
expressions on
on neutrophils
neutrophils in
P2X7
expressions
on on
total
Figure
in the
the discovery
discoverycohort.
cohort.(A)
(A)
P2X7
expressions
total
neutrophils (left) and CD14−−CD16++++neutrophils (right) between in Aβ −ve controls (Aβ−) and Aβ +ve
neutrophils (left) and CD14 CD16 neutrophils (right) between in Aβ −ve controls (Aβ−) and Aβ
cases (Aβ+). Bar graphs illustrated the boxplot distribution of individual measurements with “x”
+ve
cases (Aβ+).
BarTwo
graphs
illustrated
thewas
boxplot
distribution
of (B)
individual
measurements
with
denoting
the mean.
group
comparison
determined
by t-test.
P2X7 expressions
on CD14
++ neutrophils
“x”
denoting
the mean.
Two group
comparison
was determined
(B) P2X7
expressions
CD16
between
CN (CN−:
CN −ve), pre-clinical
(CN+: by
CNt-test.
+ve), and
AD with
dementia on
− CD16++
(Dementia:
MCI
+ve and AD)
individuals.
Bar−graphs
the boxplot
distribution
individCD14
neutrophils
between
CN (CN
: CN −illustrated
ve), pre-clinical
(CN+:
CN +ve), of
and
AD with
ual measurements
“x”
denoting
theindividuals.
mean. Three-group
comparison
was
determined
by onedementia
(Dementia:with
MCI
+ve
and AD)
Bar graphs
illustrated
the
boxplot distribution
ANOVA
followed by multiple
using
Dunnett’s
post-hoc
test (solid line).
ofway
individual
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with “x”comparison
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Lymphocyte surface expression of P2X7 also demonstrated similar results. P2X7 ex− total lymphocytes, CD14−CD16+ NK cells, and CD14−CD16− T and B
pression
on CD14
2.1.2. Reduced
Monocyte
Surface P2X7 Expressions in Aβ +Ve Cases in Validation Cohort
lymphocytes were reduced significantly in Aβ +ve cases compared with Aβ −ve controls
After identifying the global downregulation of leukocyte surface P2X7 in Aβ +ve cases
with effect sizes of −0.572, −0.509, and −0.559, respectively (Figure 4A; Table S1). P2X7
in the discovery cohort, we drew at random a second group of 111 participants from the
expression on NK cells were the highest among lymphocyte subtypes (Figure 4A), which
AIBL study to validate our results (the validation cohort A, Table 1). In validation cohort
was significantly lower in CN +ve and dementia groups compared with CN −ve group,
A, FITC-conjugated anti-P2X7 antibodies were used to study P2X7, so the value of MFI
with effect sizes of −0.550 and −0.758, respectively (Figure 4B; Table S2). Moreover, P2X7
was not comparable between the two cohorts. A global downregulation of cell surface
expressions on all lymphocyte subtypes were associated positively with neuropsychologP2X7 expressions on all leukocyte subtypes were observed (Table S3). Both monocyte
ical score (PACC) (Figure 4C–E).

and neutrophil surface P2X7 expressions showed significant differences between Aβ +ve
cases and Aβ −ve controls (Table S3). P2X7 expression on non-classical monocytes were
significantly lower in Aβ +ve cases compared with Aβ −ve controls with effect size of
−1.233 (Figure 5A; Table S3). The validation cohort were further categorised into CN −ve,
CN +ve, MCI −ve, and dementia groups. By comparing CN −ve and CN +ve groups,
P2X7 expression on non-classical monocytes was significantly lower in CN +ve group with
effect size of −1.183 (Figure 5C; Table S4). By comparing MCI −ve and dementia groups,
no differences were observed (Figure 5B–D).
To repeat the analysis of the bimodal cohorts at the discovery stage, we separated
the P2X7-high CN −ve group from the P2X7-low CN −ve group by the mean MFI of
P2X7 on classical monocytes (Figure 5B). P2X7-low CN −ve individuals were characterised
by higher EM and PACC compared with P2X7-high CN −ve individuals (Figure 6A,B).
Regarding brain volumetrics, P2X7-low CN −ve individuals were likely to present a faster
expanding rate of ventricle and faster shrinking rate of hippocampus (Figure 6D–F).
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cases in the discovery cohort, we drew at random a second group of 111 participants from
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Neutrophil surface CD11b expression was associated positively with T-tau concentration in
CSF and neutrophil surface P2X7 expression (Figure S1B,F), but no significant associations
were found with CSF P-tau181P, Aβ burden, and PACC (Figure S1C–E).
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To repeat the analysis of the bimodal cohorts at the discovery stage, we separated the
P2X7-high CN −ve group from the P2X7-low CN −ve group by the mean MFI of P2X7 on
Another integrin of interest was CD11c, which was highly expressed on monocytes
classical monocytes (Figure 5B). P2X7-low CN −ve individuals were characterised by
compared with lymphocytes and neutrophils (Figure 8A). CD11c expressions on lymhigher EM and PACC compared with P2X7-high CN −ve individuals (Figure 6A,B). Rephocytes, monocytes, and neutrophils were reduced significantly in Aβ +ve cases comgarding brain volumetrics, P2X7-low CN −ve individuals were likely to present a faster
pared with Aβ −ve controls with effect sizes of −0.701, −0.639, and −0.580, respectively
expanding rate of ventricle and faster shrinking rate of hippocampus (Figure 6D–F).

(Figure 8A; Table S1). Compared with CN −ve individuals, monocyte surface CD11c expression in CN +ve and dementia individuals was significantly lower with effect sizes
of −1.054 and −1.249 (Figure 6B; Table S1). Moreover, CD11c expression on monocytes
was associated negatively with ventricle volume while associated positively with P2X7
expression on monocytes (Figure 8C,D). Similarly, neutrophil surface CD11c expression
was significantly lower in CN +ve and dementia individuals compared with CN −ve individuals (Figure S2A). It was strongly associated with neutrophil surface P2X7 expression,
while trended towards a significant association with ventricle volume (Figure S2B,C).
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2.2. Strong Correlation between P2X7 Expressions and Integrin Expressions
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lymphocytes (Figure 7A). In Aβ +ve cases, lower CD11b expressions on monocytes and
followed by calculating their relative percentages in total monocyte population. Although
neutrophils were observed with effect sizes of −0.651 and −0.526, respectively (Figure 7A;
the percentages of these monocyte sub-populations did not differ significantly between Aβ
Table S1). By categorising the discovery cohort into CN −ve, CN +ve, and dementia
+ve cases and Aβ −ve controls, they were associated with CSF measurements of Aβ1-42 ,
groups, both CN +ve and dementia individuals presented significantly lower CD11b exT-tau, and P-tau181P (Figure S3). Non-classical monocytes and intermediate monocytes
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Regarding
CD11b expression
on peripheral neutrophils, we did not observe significant differences across CN −ve, CD +ve,
and dementia groups (Figure S1A). Neutrophil surface CD11b expression was associated
positively with T-tau concentration in CSF and neutrophil surface P2X7 expression (Figure S1B,F), but no significant associations were found with CSF P-tau181P, Aβ burden,
and PACC (Figure S1C–E).
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pression in CN +ve and dementia individuals was significantly lower with effect sizes of
−1.054 and –1.249 (Figure 6B; Table S1). Moreover, CD11c expression on monocytes was
associated negatively with ventricle volume while associated positively with P2X7 expression on monocytes (Figure 8C,D). Similarly, neutrophil surface CD11c expression was significantly lower in CN +ve and dementia individuals compared with CN −ve individuals
12 of 22
(Figure S2A). It was strongly associated with neutrophil surface P2X7 expression, while
trended towards a significant association with ventricle volume (Figure S2B,C).
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We also used anti-HLA-DR antibodies to identify HLA-DR+ monocyte subpopulation. In the discovery cohort, the percentage of HLA-DR+ monocytes in total monocyte
population was lower in Aβ +ve cases compared with Aβ −ve controls, supported by
higher HLA-DR− monocytes in Aβ +ve cases (Figure S4A). By categorising the discovery
cohort into CN −ve, CN +ve, and dementia, HLA-DR+ monocytes were significantly lower
in dementia group compared with CN −ve controls (Figure S4B). Furthermore, HLADR+ monocytes were associated negatively with ventricle volume and its rate of change
(Figure S4C,D), while associated positively with the rate of change of cortical grey matter
volume (Figure S4E). Regarding neuropsychological assessments, HLA-DR+ monocytes
were associated positively with PACC (Figure S4F). HLA-DR+ monocytes were further associated with P2X7 expressions on total monocytes and classical monocytes (Figure S4G,H).
To validate these findings, we further drew another independent cohort comprising of
88 participants from the AIBL study (Validation cohort B, Table 1). We failed to observe
significant differences of HLA-DR+ monocytes between Aβ +ve cases and Aβ −ve con-
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trols (S5A). By categorising the validation cohort B into CN −ve, CN +ve, MCI− ve, and
dementia groups, the percentage of HLA-DR− monocytes were significantly higher in
dementia individuals compared with MCI −ve individuals (Figure S5B). Additionally,
HLA-DR+ monocytes were associated positively with the rate of change of cortical white
matter volume (Figure S5C). Regarding neuropsychological scores, HLA-DR+ monocytes
were associated positively with EM and its rate of change (Figure S5D,E), while HLA-DR−
monocytes was associated negatively with EM and its rate of change (Figure S5F,G).
2.4. Unchanged Polygenic Risk Scores (PRS) of P2X7 in AD
We developed a PRS comprised of 12 P2RX7 and P2RX4 single nucleotide polymorphisms (SNP), which were associated with neurodegeneration and P2X7 function. A total
of 12 neurodegeneration-related SNPs were selected from our previous functional studies
and literature, including 12 SNPs in P2RX7 and one SNP in P2RX4 (Table S5). Among
the 12 SNPs, ten of them were associated with the pore formation function of P2X7, while
three of them were associated with the innate phagocytic function of P2X7 (Table S5).
Traditionally, the effect sizes of risk alleles are determined by summary statistics of relevant
genomic studies. In this study, we arbitrarily determined their effect sizes according to
the functional assessments of P2RX7 SNPs by our group and literature (Table S5). Given
the dual functionality of P2X7, two PRS were generated. PRS-pore was determined by ten
genetic variants associated with pore formation function of P2X7 (Table S5). PRS-phago was
then determined by three genetic variants associated with the innate phagocytic function
of P2X7 (Table S5). A total of 1738 participants were recruited from the AIBL database
(n = 919) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (n = 819).
By excluding samples with missing demographics or genotyping data, 900 AIBL participants and 786 ADNI participants remained for PRS analysis. The characteristics of P2RX7
and P2RX4 SNPs in the AIBL and the ADNI cohort were summarised in Table 2. We first
used PLINK 1.9 to study whether P2RX7 and P2RX4 SNPs were associated with the clinical
diagnosis. The only SNP that reached statistical significance was rs17525809 (V76A) in
the AIBL cohort (Table S6; p = 0.05). Subsequently, we calculated two PRS depending on
the associated functions of these SNPs. The summary of PRS-pore and PRS-phago in each
cohort and the combined cohort were presented in Table 2, no differences were observed
between cases and controls.
Table 2. Characteristics of sample cohorts with two PRS calculations.
Demographics

Sample size
Sex (women)
PRS-pore
PRS-phago

AIBL

n
n
%
mean
SD
mean
SD

ADNI

Combined

CN

MCI

AD

CN

MCI

AD

CN

MCI

AD

647
377
0.583
0.293
0.958
−0.057
0.192

77
40
0.520
0.292
1.063
−0.077
0.240

176
102
0.580
0.321
0.984
−0.054
0.187

255
134
0.526
0.243
0.958
−0.050
0.170

379
154
0.406
0.282
1.063
−0.056
0.207

152
61
0.401
0.191
0.984
−0.069
0.197

902
511
0.567
0.279
0.947
−0.055
0.186

456
194
0.425
0.284
0.940
−0.059
0.213

328
163
0.497
0.261
0.962
−0.061
0.192

3. Discussion
3.1. Reduced Peripheral Leukocyte Surface P2X7 Expressions in Aβ +Ve Cases
Dysregulated immune responses have been raised as a possible contributor to AD
pathogenesis and this study compared P2X7 expressions on adaptive and innate immunerelated cells between Aβ +ve cases and Aβ −ve controls. We demonstrated globally
reduced P2X7 expressions on peripheral leukocytes in Aβ +ve cases, including lymphocytes, monocytes, and neutrophils, as previously reported by our group [11]. Leukocyte
surface P2X7 expressions were further associated with brain atrophy, neuropsychological
estimates, and CSF biomarkers. These results indicated that patients with low leukocyte
P2X7 expressions were likely to present higher Aβ burden, more severe brain atrophy,
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more compromised cognitive, learning, and memorising abilities in AD. While our results
demonstrated P2X7 downregulation on monocytes, P2X7 upregulation was found in microglia near Aβ plaques in the brains of AD patients and AD mice models [16]. P2X7
is a dual-functional purinergic receptor that acts as an ATP-induced pro-inflammatory
ion channel in ATP-rich environment [13]. Its pro-inflammatory function has been well
associated with AD [13]. One possible mechanism of P2X7 upregulation in AD brain is
due to the overexpressed transcriptional factor specificity protein 1 (SP1), as shown in
mice model of AD [17]. Recent genomic study of AD has revealed that SP1 is one of the
over-represented motifs found in the active enhancers of myeloid cells and these enhancers
might upregulate many AD GWAS risk genes [18]. P2X7 upregulation in the central pool
of AD patients and in mice models of AD has been widely demonstrated, but the reasons
underlining P2X7 downregulation in the periphery awaits further elucidation.
3.2. Are Low P2X7, CD11b, and CD11c Expressions Indicative of Pre-Clinical AD?
Following recognising differential P2X7 expressions in individuals with different PETAβ status, we further compared P2X7 expressions by including both PET-Aβ status and
clinical symptoms. In the discovery cohort, due to the lack of prodromal AD patients
(MCI −ve), only three groups were categorised: CN individuals (CN −ve), pre-clinical
AD patients (CN +ve), and AD patients with dementia (Dementia: MCI +ve and AD).
P2X7 expressions on monocytes and neutrophils were significantly lower in pre-clinical
AD patients compared with CN individuals. P2X7 downregulation may happen early
at the pre-clinical stage of AD and stayed stable throughout disease course, but the underlying mechanism remains unknown. Interestingly, P2X7 expressions on lymphocytes
and monocytes resembled bimodal distribution, in which over half of CN individuals
expressed high level of P2X7, while the others expressed low level of P2X7. Compared
with CN individuals with high level of P2X7, CN individuals with low level of P2X7 were
characterised by higher CSF Aβ1-42 /T-tau ratio, higher CSF Aβ1-42 /P-tau181P ratio, and
better cognition (higher EM). They were likely to present faster expanding rate of ventricle
and faster shrinking rate of hippocampus. AD progression is characterised by low CSF
Aβ1-42 , high CSF Tau, high CSF pTau181, low CSF Aβ1-42 /Tau ratios [19], and low EM.
Therefore, CN individuals with low level of P2X7 were not expected to present high CSF
Aβ1-42 /T-tau ratio or high EM. It suggested that CN individuals with low P2X7 level may
undergo uncharacterised pathological changes and progress into the pre-clinical stage
of AD soon, but more investigations are required to elucidate P2X7 downregulation in
AD pathogenesis and progress. This pre-clinical P2X7 downregulation may be associated
with its function as a scavenger receptor responsible for innate phagocytosis in serum-free
environment [13]. In the central pool of AD individuals, ATP-induced P2X7 pore activation dissociates transmembrane P2X7 from intracellular actin cytoskeleton and attenuates
microglial phagocytic capacity [20]. However, the required concentration of ATP for P2X7
pore activation can be rarely achieved in bloodstream or CSF (>100 µM, but usually 1–5 mM
depending on ambient divalent cations) [13]. This suggests that a higher proportion of P2X7
receptors may tightly attach to actin cytoskeleton, directing more P2X7 towards scavenger
function mediating phagocytosis [11]. Whether peripheral P2X7 downregulation at the
pre-clinical stage of AD is associated with compromised phagocytotic ability or attenuated
pro-inflammatory responses awaits further investigation.
Integrin downregulation in Aβ +ve cases was also observed, particularly on professional phagocytes—monocytes and neutrophils. CD11b and CD11c play important roles
in the recruitment and migration of mononuclear phagocytes, cell-cell contact formation,
and immune cell signalling [21]. They also pair with the β2 integrin subunit, CD18, to
form complement receptor 3 (CR3) and 4 (CR4) respectively, mediating complement-coated
particle phagocytosis [21]. Several studies had identified increased CD11b and CD11c levels
in the brains of AD patients compared with CN individuals [22], but our results reported
the contradictory facts in bloodstream. Both integrins were downregulated significantly at
the pre-clinical stage of AD. Leukocyte surface integrin expressions were further associated
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with CSF biomarkers, cognitive decline (PACC), and ventricle enlargement. Interestingly,
the simultaneous downregulation of integrins and P2X7 was demonstrated, indicating that
the pre-clinical AD patients expressed both low levels of P2X7 and integrins on their monocytes and neutrophils, which stayed low throughout disease course. Their downregulation
in the periphery might significantly compromise the phagocytic and migrating abilities of
monocytes and neutrophils from the pre-clinical AD stage to the AD with dementia stage.
3.3. Altered Peripheral Monocyte Subpopulations in AD
Given that our discoveries of P2X7 and integrins converge on innate immunity and
monocytes, we further dissected monocyte population into CD14+ CD16− classical monocytes, CD14dim CD16+ non-classical monocytes, and CD14+ CD16+ intermediate monocytes
to study their associations with AD. Progression of AD can be characterised by low CSF
Aβ1-42 , high CSF T-tau, high CSF P-tau181P, and low CSF Aβ1-42 /T-tau ratio [19]. As AD
progressed, we observed fewer intermediate monocytes, fewer non-classical monocytes,
but more classical monocytes in bloodstream in the discovery cohort. Classical monocytes
are professional phagocytes, occupying 80% of total population [23]. Intermediate monocytes are expertise at antigen presentation, cytokine secretion, apoptosis regulation, and
transendothelial migration [23]. The infiltration of intermediate monocytes into the CNS
due to leaky BBB remains debatable and our findings provide indirect evidence of infiltrative intermediate monocytes into the brain [24]. Furthermore, we also studied HLA-DR+
monocytes to investigate adaptive immunity in AD progression. Our discovery cohort
illustrated significantly fewer HLA-DR+ monocytes in AD cases with dementia compared
with CN individuals, as supported by more HLA-DR− monocytes in the AD cases with
dementia. Previous study showed reduced HLA-DR+ CD14+ monocytes and increased
HLA-DR+ CD16+ monocytes during AD progression. HLA-DR+ monocytes were further
associated with brain atrophy, neuropsychological estimates, and leukocyte surface P2X7
expressions. These observations further consolidate the involvement of both innate and
adaptive immunity in AD, suggesting compromised phagocytic capacity at the pre-clinical
stage of AD and altered antigen presentation ability of professional mononuclear phagocytes at the dementia stage of AD. Moreover, reduced CD16− monocytes (classical) and
increased CD16+ monocytes (non-classical and intermediate) in the blood circulation of
AD patients were also noted and whether this phenomenon is associated with infiltrative
monocytes into the CNS awaits further investigation.
3.4. P2X7 Alterations in AD Were Not Caused by Genetic Factors
To further assess the association between P2X7 function and AD, we selected 12 SNPs
in P2RX7 and P2RX4 genes that are known to inhibit or promote the pore formation
function or phagocytic function of P2X7. However, no significant association was found
between the P2RX7 gene and AD. This observation is reasonable because no P2RX7 SNP
has been identified as a risk allele in AD GWAS [4]. Further PRS analysis with added
functional notes did not show any difference between MCI/AD cases and CN controls
either. Therefore, the changes of P2X7 expression on leukocytes may not be determined by
genetic factors but may be regulated by environmental factors instead. It suggested that
P2X7 expression level is highly modifiable as AD progressed, making P2X7 a promising
therapeutic target.
3.5. Limitations of Current Study
All participants were recruited in Perth and Melbourne through the AIBL study,
and the ethnic background was limited to 99.9% Caucasians who were fluent in English.
The application of our findings to general population would require more investigations
by involving participants with various ethnic backgrounds. Second, our study showed
interesting associations with CSF measurements of Aβ1-42 , Tau, and pTau181. However, CSF
data were scarce, and we need to collect more CSF measurements to validate our findings.
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4. Materials and Methods
4.1. Flow Study: Study Individuals, Ethical Approvals, and Blood Samples
A total of 287 participants were drawn at random from the AIBL study. The AIBL
study is a dual-site, longitudinal, prospective, observational study that integrated data
from neuroimaging, biomarkers, lifestyle, clinical, and neuropsychological analyses [25].
This is a two-stage study, comprising of a discovery stage (n = 88), a validation stage A for
the P2X7 study (n = 111), and a validation stage B for the HLA-DR study (n = 88) (Table 1).
The participants in all stages were independent and all accident duplicated participants
had been removed. All participants were over 65 years old and fluent in English. The
clinical classification of disease status, namely CN, MCI, and AD dementia, was assessed
by neuropsychological examinations, as defined by NINCDS-ADRDA criteria [26–28]. The
summary of participants’ demographics and clinical characteristics was demonstrated in
Table 1.
Peripheral whole blood was collected via venepuncture between 8:00 a.m. and
10:30 a.m. following overnight fasting. Whole blood was kept in EDTA anti-coagulant
Vacutainer® tube (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) and was kept
on ice during transportation. Processing of whole blood was completed within three hours
after collection.
This study was approved by the Eastern Health Research and Ethics Committee (Ref:
E05/1011, since Sep 2010) and conducted according to Declaration of Helsinki principles.
All participants and patient caregivers completed written informed consent. All clinical and
demographic information was masked until the collection of all laboratory measurements.
4.2. PRS Study: Study Individuals and Ethical Approvals
A total of 1738 participants were recruited from the AIBL database (n = 919) and the
ADNI database (n = 819). ADNI was initiated in 2003 in the United States and Canada,
aiming at the development of standardized imaging procedure and biomarker assessment
in normal, preclinical, and prodromal patients with AD. The demographics and characteristics of these two datasets were summarised in Table 2. Regional ethical committees of
all institutions included in ADNI approved of the study and all subjects have provided
informed consent.
4.3. Flow Study: Materials and Immune Staining
Fluorophores conjugated antibodies were purchased from BD Bioscience (Franklin
Lakes, NJ, USA) and DAKO (Agilent Technologies, Santa Clara, CA, USA). The anti-human
P2X7 monoclonal antibodies were produced from the L4 clone in house [29] and conjugated
with Alexa 647 or Alexa 488 using the antibody conjugation kit from Molecule Probes
(Thermo Fisher Scientific, Waltham, MA, USA).
Cell surface staining was carried out following the BD standard protocol. Aliquots of
100 µL of fresh whole blood were added into fluorescence-activated cell sorting (FACS® )
tubes with pre-mixed antibody cocktails. An autofluorescence tube containing only whole
blood and an IgG isotype control (BD Australia, Macquarie Park, NSW, Australia) tube were
prepared for each AIBL sample. Titration of each antibody was determined by saturation
tests. Blood/antibody mixture was incubated for 15 min at room temperature with gentle
shake, followed by incubating with 2 mL of BD FACS Lysing solution (Cat#555899) for
another 15 min. 2 mL of PBS was added to each FACS® tubes, followed by centrifuging
at 1400 rpm for 3 min. Supernatant was discarded and leukocytes were resuspended into
200 uL of PBS. Leukocytes were then analysed using FACSCaliburTM (BD Biosciences) and
flow results were primarily analysed using FlowJo software (V10, FlowJo, LLC, Ashland,
OR, USA).
4.4. Flow Study: Magnetic Resonance Imaging (MRI)
The MRI scans of every participant were performed as previously described [30,31].
Images were acquired using a standard three-dimensional magnetisation-prepared rapid
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gradient echo sequence at 3 T, with in-plane resolution 1 × 1 mm, slice thickness 1.2 mm, repetition time (TR)/echo time (TE)/T1 = 2300/2.98/900, flip angle 9◦ , field of view 240 × 256,
and 160 slices. Axial T2-weighted MR images were acquired using a standard twodimensional turbo spin echo sequence at 3 T, with in-plane resolution 0.9375 × 0.9375 mm,
slice thickness 3 mm, TR/TE = 3400/101, flip angle 150◦ , field of view 228 × 256, and
48 slices. All T1-weighted (T1W) images were first corrected for bias field using the N4 algorithm [32] and smoothed using anisotropic filtering. T2W images were motion corrected
using inverse interpolation [33]. For each participant, all images were first segmented
into grey matter (GM), white matter (WM), ventricle, hippocampus, and cerebrospinal
fluid (CSF) in their native space using an in-house implementation of the Expectation
Maximization Segmentation algorithm [32].
4.5. Flow Study: PET-Aβ Imaging
Most participants underwent PET-Aβ imaging as previously described [34]. All PETAβ scans were spatially normalised using CapAIBL [31] and quantified using the Centiloid
(CL) scale [35,36]. CL of 25 was used as the cut-off point of PET-Aβ positivity.
4.6. Flow Study: EM Score
The rationale, development, and validation for the EM composite scores had been
previously detailed [37,38]. Firstly, we standardised scores for the Scores for the California
Verbal Learning Test (Second Edition, CVLT-II) delayed recall, Logical Memory delayed
recall, and Rey Complex Figure Test delayed recall, using the baseline mean and the
baseline mean and standard deviation for the entire sample of the CN older adult group in
AIBL. The EM composite score was then formed by averaging the standardised scores.
4.7. Flow Study: PACC Score
The rationale, development, and validation for the PACC had been previously described [39,40]. We first standardised scores for the California Verbal Learning Test (Second
Edition, CVLT-II) delayed recall, Logical Memory delayed recall, Digit Symbol Coding,
and MMSE, using the baseline mean and standard deviation for the entire sample of the
cognitively normal older adult group in AIBL. The PACC was then calculated by averaging
the standardised scores.
4.8. Flow Study: CSF Measurements of Biomarkers
The collection, processing, measurement, and long-term storage of CSF samples
had been previously described [6]. CSF was collected in the morning by routine lumbar
puncture after overnight fasting, using a similar protocol recommended by the Alzheimer’s
Biomarkers Standardisation Initiative [41]. CSF was tested routinely using the INNOTEST®
kit assay (Innogenetics, now Fujirebio Europe N.V., Ghent, Belgium) for Aβ1-42 , total Tau,
and pTau181.
4.9. Flow Study: Calculation of Progressive Changes
As a longitudinal study, most participants of AIBL have undergone long-term followup concerning brain imaging, cognitive assessments, and other pathological examinations
in 18-month intervals. Most participants in this study had 2–6 visits to AIBL clinics, which
enabled researchers to investigate progressive changes of their pathological tests. The
yearly slopes of PET-Aβ scans, MRI, EM, and PACC were calculated from at least two time
points using the Excel “Slope” function.
4.10. Flow Study: Statistical Rational
Before conducting statistical analysis, qqPlot() and barlett.test() in R were used to
assess normality and homogeneity of variances, respectively. Sample characteristics of
age, sex, APOE ε4 carriers, year of education, and neuropsychological assessments were
compared using one-way ANOVA (continuous variables) and chi-square test (categoric
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variables). The comparisons of leukocyte receptors were first performed between Aβ +ve
cases and Aβ −ve controls by t-test using the oneway.test() function in R. In discovery
cohort (no prodromal cases), the subsequent comparisons of receptors between CN −ve,
CN +ve, and demented cases were determined by one-way ANOVA using oneway.test()
function in R. Its post-hoc tests were calculated by Dunnett’s test using the DunnettTest() in
R. In validation cohort, the comparisons between CN +ve and CN −ve and the comparisons
between demented AD cases and prodromal AD cases were calculated by t-test using the
oneway.test() function in R. The correlations between receptors and Aβ burden, brain
volumes, neuropsychological assessments, and CSF measurements of Aβ1-42 , T-tau, and Ptaau181P were determined by calculating Pearson product-moment correlation coefficients
(r) using the cor() function in R. After dissecting the CN controls by mean P2X7 MFI,
two-group comparisons were determined by student t-test using oneway.test() in R. All
statistical plots were generated using the ggplot() function in R. R version 3.6.3 (29 February
2020)—“Holding the Windsock” Copyright (C) 2020 The R Foundation for Statistical
Computing Platform: x86_64-w64-mingw32/x64 (64-bit).
4.11. PRS Study: Genotype Data, PRS Calculation, and Data Analysis
Data was available across 919 individuals in AIBL database and 809 individuals in
ADNI database. Prior to data analysis, data from each databased were QC’ed separately
using PLINK (1.9, Shaun Purcell, https://pngu.mgh.harvard.edu/purcell/plink/ accessed
on 12 October 2013). A total of 12 neurodegeneration-related P2RX7 and P2RX4 SNPs were
selected from our previous functional studies and literature, including 11 SNPs in P2RX7
and one SNP in P2RX4 (Table 2; Tables S6 and S7). The classical PRS is an estimate of an
individual’s genetic liability to a disease by their genotype profile and effect sizes of each
allele determined by genome-wide association study [42]. Instead of classic procedure, the
effect sizes of risk alleles in this study were determined by functional assessments of P2RX7
SNPs by our group and literature (Table S5). Two PRS were calculated. The first PRS-pore
was determined by 10 genetic variants that had been associated with pore formation of
P2X7 (Table S5). The second PRS-phago was determined by three genetic variants that had
been associated with the innate phagocytic function of P2X7 (Table S5).
5. Conclusions
We identified the downregulation of P2X7, CD11b, and CD11c on peripheral leukocyte surface at the pre-clinical stage of AD and they were further associated with brain
atrophy, cognition decline, and CSF biomarkers of AD. Their significant associations with
the current diagnostic standards of AD strengthened their involvement in early stage of
disease course, suggesting that the dysfunction of pro-inflammatory responses, phagocytic
functions, and migrating abilities of circulating phagocytes may happen at the pre-clinical
stage of AD and stay compromised throughout disease course. On the contrary, the antigen
presentation function of circulating monocytes may be altered at the dementia stage of
AD. Our results consolidate that AD is a systemic disease modulated by both central and
peripheral immune responses, in which altered innate immune responses may happen
at asymptomatic stage of AD while altered adaptive immune responses happen at symptomatic stage of AD. Most interestingly, low level of P2X7 expression on monocytes might
indicate patients who had faster shrinking rate of hippocampus but normal Aβ burden
and cognitive function. Given that altered immune responses had been raised as a strong
contributor to AD progression, as supported by many genetic studies, our study deepens
the understanding of the peripheral immune dysfunction at the pre-clinical stage of AD.
This not only improves the understanding of the role of immunity in AD pathogenesis, but
also provides novel insights into biomarker discovery. Leukocyte surface expression of
immune-related receptors, such as P2X7 and integrins, might be promising biomarkers of
AD, which might facilitate the diagnosis and prognosis of pre-clinical AD patients. Given
the over 60 microglial-specific AD risk genes identified by AD GWAS, it is promising to
study these immune-related markers on professional phagocytes to improve our under-
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standing of immune involvement in AD and to provide more insights into biomarker
discovery and therapeutic development.
Supplementary Materials: The following supporting information can be downloaded at: https://
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